Based on these Phase 1b results, Herantis intends to advance HER-096 into a Phase 2 clinical trial during 2026 to evaluate the efficacy, safety and tolerability of HER-096 in early-stage Parkinson’s patients, it states.

“We are thrilled to achieve this important milestone, successfully meeting the trial’s primary and secondary endpoints. These results are a testament to our team’s expertise and dedication, demonstrating our ability to drive the development program forward efficiently. We sincerely thank the Parkinson’s patients participating in this trial, other contributors, and patient organizations, the Michael J. Fox Foundation and Parkinson’s UK, for their support and engagement in this study. We are now excited to advance this program to Phase 2 as we explore HER-096’s potential to become the first disease-modifying therapy for Parkinson’s disease,” says Antti Vuolanto, CEO of Herantis Pharma.